Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EE6L
|
|||
| Former ID |
DNC005570
|
|||
| Drug Name |
BP-897
|
|||
| Synonyms |
BP 897; BP-897; BP897; UNII-2FVL90IM8I; 2FVL90IM8I; CHEMBL25236; 314776-92-6; N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide; N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]naphthalene-2-carboxamide; BP-897 free base; SPBio_002558; SR-01000075725; DO-687; Prestwick-07H10; Prestwick3_000559; Prestwick2_000559; Prestwick1_000559; Prestwick0_000559; Lopac-B-9308; 2-Naphthalenecarboxamide, N-(4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl)-; AC1MI4Y9; Lopac0_000165; BSPBio_000637; SCHEMBL2125882; GTPL7625; BPBio1_000701
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cocaine addiction [ICD-11: 6C45.2; ICD-10: F14.2; ICD-9: 304.2] | Discontinued in Phase 2 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H31N3O2
|
|||
| Canonical SMILES |
COC1=CC=CC=C1N2CCN(CC2)CCCCNC(=O)C3=CC4=CC=CC=C4C=C3
|
|||
| InChI |
1S/C26H31N3O2/c1-31-25-11-5-4-10-24(25)29-18-16-28(17-19-29)15-7-6-14-27-26(30)23-13-12-21-8-2-3-9-22(21)20-23/h2-5,8-13,20H,6-7,14-19H2,1H3,(H,27,30)
|
|||
| InChIKey |
MNHDKMDLOJSCGN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 192384-87-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
11110867, 11110868, 11466587, 11467707, 11486294, 11564242, 14782328, 17404728, 24278279, 36106208, 47349351, 48018895, 48094533, 48243353, 48393921, 49698551, 50105904, 50105905, 53777271, 53790769, 57353732, 79551160, 85208979, 85230943, 85788982, 90340615, 92303556, 103194907, 103856467, 104012598, 111646208, 121360835, 124749503, 124879457, 128620357, 134342775, 140156791, 144240233, 144240235, 162220559, 163564119, 172649623, 198955573, 223365960, 228262829
|
|||
| ChEBI ID |
CHEBI:92310
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine D3 receptor (D3R) | Target Info | Modulator | [3] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Dopaminergic synapse | ||||
| Reactome | Dopamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7625). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012397) | |||
| REF 3 | BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction.CNS Drug Rev.2003 Summer;9(2):141-58. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.